肝细胞癌诊断时血清甲胎蛋白水平呈下降趋势
Decreasing Trend of Serum α-Fetoprotein Level in Hepatocellular Carcinoma.
PubMed 文献 · Clin Gastroenterol Hepatol · 2021-08-12
该研究基于美国人群,假设随着肝细胞癌早期检出增加及病因从病毒性向非病毒性转变,诊断时血清甲胎蛋白(AFP)水平会下降。原文未报告具体研究设计与样本量,也未给出下降幅度或统计检验结果。
要点
- AFP是肝细胞癌超声监测早期检出的重要生物标志物。
- 肿瘤负荷、种族/民族及肝病病因均可影响AFP水平。
- 美国肝细胞癌早期检出增加及病因转变可能使诊断时AFP下降。
核心结论
- 原文假设美国肝细胞癌诊断时血清AFP水平会随早期检出增加和病因从病毒性向非病毒性转变而下降,但未报告验证结果。
研究设计与样本
- 原文未报告具体研究设计与样本量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Serum α-fetoprotein (AFP), a well-established biomarker for hepatocellular carcinoma (HCC), increases the sensitivity of ultrasound-based surveillance programs for early stage HCC detection.1,2 Multiple factors, including tumor burden, can affect AFP levels in patients with HCC.3 Nontumoral factors, such as race/ethnicity and liver disease etiology, are also known to be associated with elevated AFP.3 With the increasing trend of earlier stage HCC detection and shift from viral to nonviral etiology, we hypothesized that AFP level at HCC diagnosis would decrease in the United States.
来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。
引用
- Vipani A, Lauzon M, Luu M, et al. Decreasing Trend of Serum α-Fetoprotein Level in Hepatocellular Carcinoma. Clin Gastroenterol Hepatol. 2021. PMID: 34391921. doi:10.1016/j.cgh.2021.08.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。